Isolated Hepatitis B Core Antibody

Slides:



Advertisements
Similar presentations
Hepatitis B & Hepatitis C in HIV
Advertisements

Egyptian Guidelines For Management of Chronic Hepatitis B
HBV and HIV HIV and HBV VG Naidoo Gastroenterology.
CHER Trial: Early Antiretroviral Therapy and Mortality Among HIV- Infected Infants New England J Med 2008;359 (21):
Treatment appropriate Normal or minimal hepatitis Chronic hepatitis Normal or inactive hepatitis Progressive fibrosis Cirrhosis HCC HBeAg Anti-HBe HBV.
Acute Retroviral Syndrome
Hepatitis B Virus (HBV) and HIV Current Management Strategies Gregory P. Melcher, M.D. Division of Infectious Diseases UC Davis AETC.
BORDERNETwork Training on HIV and HBV Co-Infections Dr. med. Wolfgang Güthoff / Alexander Leffers, M.A.
Hepatitis B.
Hepatitis B and Hepatitis B Vaccine Epidemiology and Prevention of Vaccine- Preventable Diseases National Center for Immunization and Respiratory Diseases.
Hepatitis B 101 Clinical presentation of Hepatitis B Virus (HBV) indistinguishable from other hepatitis causes and is quite variable from asymptomatic.
Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.
Hepatitis B: Epidemiology
BLOOD BORNE PATHOGEN EXPOSURE Management – What you need to know about Needlesticks and Splashes Amy J. Behrman, MD Occupational Medicine Dept of Emergency.
Slide #1 CL Thio, MD. Presented at RWCA Clinical Update, August Optimizing Hepatitis B Virus Treatment in HIV-Infected Individuals Chloe L. Thio,
N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER 2014 IAS-USA Treatment Guidelines Brian R. Wood, MD Medical Director, NW AETC ECHO Assistant Professor.
HEPATITIS B MARKERS AND VACCINE
Hepatitis web study H EPATITIS W EB S TUDY H. Nina Kim, MD Assistant Professor of Medicine Division of Infectious Diseases University of Washington School.
HIV Testing CDC power point edited by M. Myers
HEPATITIS A VIRUS Week Response Clinical illness ALT IgM IgG HAV in stool Infection Viremia EVENTS IN HEPATITIS A VIRUS INFECTION.
Faculty of Allied Medical Sciences Clinical Immunology & Serology Practice (MLIS 201)
Kerriann Parchment GI CBL 2 Part 3 December 2012 Viral hepatitis serology.
Seroprevalence of HBV and HCV among Children in the Kilimanjaro Region, Tanzania Florida J. Muro, Suzanne P. Fiorillo, Christopher Odhiambo, Coleen K.
Hepatitis B Virus 28.
Epidemiology and Prevention of Viral Hepatitis A to E: Hepatitis D (Delta) Virus Division of Viral Hepatitis.
Hepatitis B and Acute Liver Failure Jack Kuritzky, PGY-2 UNC Internal Medicine Morning Report 3/12/10.
Why we are here? However, a general lack of understanding exists among health-care professionals regarding the interpretation of screening test results,
Assessing the Response to Hepatitis B Immunizations in HIV-Positive Adults: Results from the 550 Clinic cohort study Camila Calderon 1, Anupama Raghuram.
Clinicaloptions.com/hepatitis Serum HBsAg as a Predictor of Response to PegIFN in HBeAg-Positive Patients Slideset on: Chan HL, Wong VW, Chim AM, Chan.
INTRODUCTION High incidence rate High incidence rate Do not grow in the laboratory Do not grow in the laboratory Discovered in 1964 Discovered in 1964.
Hepatitis B Virus Dr R V S N Sarma., M.D., [SLIDE 1] Title Slide
Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection DR. S.K CHATURVEDI DR. KANUPRIYA CHATURVEDI.
CHRONIC HEPATITIS B SEROLOGY. Antigens HBsAg -Found on the surface of the intact virus and in serum as unattached particles -Earliest detectable marker.
Promoting Healthy Lifestyles and a Clean and Safe Environment Maximizing health department resources to identify and prevent.
1. Sustained suppression of HBV replication Decrease in serum HBV DNA to
Occult hepatitis B virus (HBV) and hepatitis C virus (HCV) viremia in women with and at-risk for HIV/AIDS Taylor L, Gholam P, Delong A, Rompalo A, Klein.
New Treatment Paradigms for Therapeutically-Naïve and Treatment-Experienced HIV Patients A Customized CME Learning Experience.
Primary HIV-1 Infection Pathogenesis, Diagnosis, and Treatment Summary of Evidence Martin Markowitz M.D. Clinical Director and Staff Investigator Aaron.
Twice Weekly Peg-IFN-alpha-2a with Ribavirin Improves Early Viral Kinetics over Standard Therapy Among HIV/HCV Co-Infected African American Patients Alison.
SPECIAL CONSIDERATIONS August
Hepatitis B The Basics David Wong University of Toronto March 2005.
Need for vaccination for vaccine preventable hepatitis in methadone maintenance treatment Randy Seewald, MD 1,2,3, Eli Kamara, BS 2, Ruy Tio, DO 1,2, Rashiah.
Hepatitis D (Delta) Virus
Viral Hepatitis Program Management of Babies Born to HBsAg- Positive Mothers Vickie Weeast Perinatal Hepatitis B Case.
Evaluation of Hepatitis B surveillance system in Armenia, 2014 AUTHORS Karine Gevorgyan Lusine Paronyan Shushan Sargsyan Artavazd Vanyan NCDC, Armenia.
N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER Major Changes to the HHS Adult and Adolescent HIV Treatment Guidelines: April 2015 Brian R. Wood, MD.
Diabetes and Obesity Journal Club Carina Signori Endocrinology Fellow
Serologic markers and molecular epidemiology of HBV from an HIV infected cohort from Cameroon Tshifhiwa Magoro 1, Emmaculate Nongpang 2, Lufuno Mavhandu.
CHRONIC HEPATITIS B SEROLOGY
Previous SVR With Interferon-Based Therapy for HCV Lowers Risk of Hepatotoxicity in HIV/HCV-Coinfected Individuals on Antiretroviral Therapy Slideset on:
Hepatitis A, B, C: Overview, Serologies, and Vaccination Connie Tien June 6, 2016.
Clinicaloptions.com/hepatitis Using Virologic and Serologic Tests in the Management of Hepatitis B Diagnose chronic HBV infection When in slideshow mode,
MICROBIOLOGY IRS. Gastroenteritis 1) Major cause of infantile death 2) Feacal-oral transmission 3) Gastroenteritis cause dehydration 4) 50 % of all causes.
Managing Occupational Risks for Hepatitis B & C Transmission in the Health Care Settings BY DR:
Adefovir Suppresses HBV DNA Levels in Lamivudine-Resistant HIV/HBV Patients Slideset on: Benhamou Y, Thibault V, Vig P, et al. Safety and efficacy of adefovir.
Hepatitis B virus infection in renal transplant recipients
Treatment of HBV/HCV Coinfection
PI project: Hepatitis B prophylaxis in patients with malignancies
In The Name of God.
Presenter ITODO EWAOCHE
Table 3 Titers of antibody to hepatitis B surface antigen (anti-HBs) 2–4 weeks after the first vaccination From: Response to Hepatitis B Vaccine in HIV-1–Positive.
Dr Iyat Abdul Sattar A study on the clinical & serolological markers of HBV among patients with chronic HBV infection in Babylon Dr Monem Makki Alshok.
The vaccination of hepatitis B in healthy adults: effect of age and sex, 2 protocols of revaccination for non-responders Jacques Choucair MD Infectious.
POST EXPOSURE PROPHYLAXIS IN HCW
Hepatitis Primary Care: Clinics in Office Practice
Division of Viral Hepatitis
Clinicaloptions.com/hepatitis Using Virologic and Serologic Tests in the Management of Hepatitis B Diagnose chronic HBV infection When in slideshow mode,
HEPATITIS B VIRUS ; WHAT`S NEW
Presentation transcript:

Isolated Hepatitis B Core Antibody Nina Kim, MD MSc Associate Professor of Medicine November 13, 2014

Isolated Core Antibody Virology & terminology Definition & Risk Factors Scenarios where we see isolated anti-HBc HBV immunization in these patients Occult hepatitis B Clinical significance Practical considerations

Hepatitis B virus Terminology HBV is partially double-stranded DNA virus. Proteins encoded by virus include: envelope, nucleocapsid, DNA polymerase. HB surface antigen is lipoprotein - part of envelope that contains the major site for binding of neutralizing antibody. HBsAg can circulate as part of virion or independently as viral particles. 2 nucleocapsid proteins: HBeAg and core Ag. HBeAg = marker of active viral replication - not uncommon for those chronically infected pts who are eAg+ to have viral levels exceeding 10 mill to 1 billion copies/mL. Loss of this - either spontaneously or thru tx - can be associated with more favorable outcomes. www.hivandhepatitis.com

Virologic & Serologic Responses to HBV http://depts.washington.edu/hepstudy

Core Antibody http://depts.washington.edu/hepstudy

Isolated Hepatitis B Core Antibody in HIV-infected Patients Definition: anti-HB core(+) but anti-HBs and HBs antigen negative Common profile – found in 20-45% in HIV-infected case series Factors associated with isolated core Ab: HIV infection Chronic hepatitis C infection Older age CD4 count <100 cells/mm3 Antiretroviral therapy: less likely to be isolated core Gandhi, J Infect Dis. 2005;191:1435-41. French, J Infect Dis 2007;195:1437-42. Sun, J Viral Hepat 2010;17:578-87. Witt, Clin Infect Dis 2013;56:606-12.

Isolated Hepatitis B Core Antibody in HIV-infected Patients Seen in 1 of these 4 scenarios: “Window phase” of acute HBV infection between loss of HB surface antigen and emergence of anti-HB surface Ab; Remote resolved HBV infection with waning of anti-HB surface Ab to level <10 IU; Chronic infection, i.e. occult HBV with HB surface Ag that has escaped detection either due to low production or mutations in envelope protein; False positive  actually never exposed to HBV Chakvetadze, Clin Infect Dis. 2010;50:1184-86. Al-Mekhaizeem, CMAJ. 2001;165:1063-4. Knoll, World J Gastroenterol. 2006;12:1255-60.

Isolated Hepatitis B Core Antibody HBV Immunization Immunization can presumably help distinguish the latter 3 scenarios: BUT most isolated core Ab patients do NOT mount an anamnestic response Scenario Vaccine Response Resolved HBV, waned sAb Anamnestic response Occult (chronic) HBV No response False positive Primary response

Isolated Hepatitis B Core Antibody HBV Immunization Study n/% Isolated Core % Anamnestic Predictors of Anamnestic Vaccine response Gandhi JID 2005 45% (n=44) 24% (7/29) Anti-HBe(+): 45% vs. 7% Jongjirawisan JAMT 2006 20% (28/140) 7% (2/28) Chakvetadze, CID 2010 N=40 32.5% (13/40) No baseline factors predictive. Among 7 nonresponders, only 1 had detectable HBV DNA Kaech, J Infect 2012 12% (73/605) 22% (8/37) Anti-HBe(+): OR 9.1, p=0.06 Our experience at Madison Clinic: 46% (13/28) anamnestic after single 20 mcg dose of hep B vaccine. Anti-HBe(+) status not predictive of this response but appeared to be associated with higher titer of anti-HBs post-vaccination. Presence of anti-HBe infers prior HBV exposure & presence of immunologic memory  less likely isolated core is false(+) Responses to vaccination have not been historically robust. In keeping with knowledge that HIV-infected individuals can have accelerated loss of anti-HBs

Isolated Hepatitis B Core Antibody Occult HBV Infection in HIV-infected Patients Defined by negative surface Ag, (+)HBV DNA level Generally not common – prevalence variable, depending on population & assays More recent US-based case series: prevalence ranges from ~2-10% among isolated core pts True prevalence may be underestimated because case series have been small with single time-point HBV measurement & some on HBV-active antivirals HBV viral levels detected typically low <1000 IU/mL range Gandhi JAIDS. 2003;34:439-40. French, J Infect Dis 2007;195:1437-42. Knoll, World J Gastroenterol. 2006;12:1255-60. Shire JAIDS. 2003;36:869-75.

Isolated Hepatitis B Core Antibody Occult HBV Infection in HIV-infected Patients

Isolated Hepatitis B Core Antibody Clinical Significance Isolated core Ab appears to be a stable pattern over time in most (84%) individuals If retested, still present (i.e. window phase or false positive unlikely) If it changes at all, transitions to/from pattern of natural immunity (anti-HBs and anti-HBc positive) Transition to/from chronic HBV infection (gain or loss of HBsAg) is rare Not consistently associated with: ALT/AST elevations (independent of HCV coinfection) Liver stiffness by FibroScan (indepenent of HCV coinfection) Witt, Clin Infect Dis 2013;56:606-12. Perez-Rodriguez, World J Gastroenterol. 2009;15:1237-41. Knoll, World J Gastroenterol. 2006;12:1255-60. Chakvetadze, Med Mal Infect. 2013;43:222-5.

Practical Considerations What Do the Guidelines Say? DHHS 2014 OI Guidelines: “Some specialists recommend that HIV-infected individuals with anti-HBc alone be tested for HBV DNA. If positive for HBV DNA they should be treated as chronically infected; if negative they should be considered still susceptible to HBV and vaccinated accordingly.” HIVMA 2014 Primary Care Guidelines: “Patients who are negative for HBsAg and HBsAb but positive for anti-HBc should be screened for chronic HBV infection by determination of HBV DNA; those without evidence of chronic infection should consider vaccination (strong recommendation, low quality evidence).”

Practical Considerations Expert Opinion Screen Isolated anti-HBc for Occult HBV with HBV DNA level: Not on tenofovir, emtricitabine or lamivudine (off ART) ALT or AST elevated Chronic hepatitis C Not responding to vaccination Hepatitis B Immunization for isolated anti-HBc: Can do either boost & check or complete series Can consider anti-HBe assessment to differentiate boost/check or simply complete series Vaccinate early (before patient’s CD4 gets <350) Always check anti-HBs 1-2 months after vaccination completed Keep in mind: Magnitude & duration of HBV vaccine response is often lower in HIV-infected patients due to a variety of factors (low CD4, detectable HIV RNA, occult HBV, other health concerns)